☆ 4.7 Article

Baricitinib for juvenile idiopathic arthritis: a monocentric case series

ANNALS OF THE RHEUMATIC DISEASES (2023)

JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis

Louise Gillard et al.

Summary: JAKi agents can be considered as a therapeutic option for difficult-to-treat Still's disease, especially for patients with partial response to medium- or high-dose corticosteroids or biologics.

RHEUMATOLOGY (2023)

添加到收藏夹

Article Pediatrics

A toddler with an unusually severe polyarticular arthritis and a lung involvement: a case report

Pietro Basile et al.

Summary: COPA syndrome is a rare inflammatory disease characterized by joint and lung involvement. In this case, a 2-year-old girl presented with intermittent limping and joint pain. After comprehensive examination and genetic testing, a diagnosis of COPA gene mutation was confirmed, and treatment resulted in significant symptom improvement.

BMC PEDIATRICS (2022)

添加到收藏夹

Letter Rheumatology

Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis

Hanna Kim et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

Nicolino Ruperto et al.

Summary: The trial showed that tofacitinib is an effective treatment for patients with polyarticular course JIA. New oral therapies are particularly relevant for children and adolescents, who might prefer to avoid injections.

LANCET (2021)

添加到收藏夹

Article Rheumatology

JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis

Elisabetta Miserocchi et al.

CLINICAL RHEUMATOLOGY (2020)

添加到收藏夹

Article Pediatrics

Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype

S. L. N. Clarke et al.

PEDIATRIC RHEUMATOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

Peter C. Taylor et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Baricitinib for juvenile idiopathic arthritis: a monocentric case series

相关参考文献

JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis

A toddler with an unusually severe polyarticular arthritis and a lung involvement: a case report

Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis

Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis

Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

导出引文

分享论文